Dr Lal Pathlabs Ltd Share Price Today - Dr Lal Pathlabs Ltd Stock Price Live NSE/BSE

Dr Lal Pathlabs Ltd

NSE: LALPATHLAB BSE: 539524

₹1367.20

(-2.19%)

Sun, 03 May 2026, 09:23 am

MTF 5xInvest in Dr Lal Pathlabs Ltd with 5x Leverage Buy with MTF

Market Cap234.16B

PE Ratio43.25

Dividend0.93

Health Services

Medical/Nursing Services

24.5K

Dr Lal Pathlabs Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
22923.20
Net Profit
492.25
P/B
9.53
Sector P/E
57.84
P/E
42.52
EV/EBITDA
25.39
Debt/Equity (Industry)
0.18
Interest Cover (Industry)
12.16
ROCE (Industry)
17.67
RONW (Industry)
14.82
ROE
24.48
ROCE
29.22
Debt/Equity
0.10
EPS (TTM)
32.76
Dividend Yield
1.79
Book Value
142.51
Interest Cover
29.01

Analysis

all

Pros

Dividends paid are well covered by earnings (2.3x coverage).
Dividends after 3 years are expected to be well covered by earnings (3.9x coverage).
Dr. Lal PathLabs's earnings growth is expected to exceed the low risk savings rate of 7.2%.
Dr. Lal PathLabs's earnings are expected to increase by more than the low risk growth rate in 3 years time.
Dr. Lal PathLabs is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).

Cons

Dividend payments have increased, but Dr. Lal PathLabs only paid a dividend in the past 4 years.
Whilst dividend payments have been stable, Dr. Lal PathLabs has been paying a dividend for less than 10 years.
Dr. Lal PathLabs's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Dr. Lal PathLabs's dividend is below the markets top 25% of dividend payers in India (3.08%).
Cash flow for Dr. Lal PathLabs is expected to increase but not above the 50% threshold in 2 years time.

Financials

Ratios

Shareholders	MAR 2026	DEC 2025	SEPT 2025	JUN 2025	MAR 2025
Promoters	53.21	53.22	53.22	53.79	53.91
FII	17.18	20.29	21.86	21.68	23.91
DII	21.38	19.21	18.49	17.91	16.08
Public	8.22	7.28	6.44	6.62	6.10
Government	0.01	0.01	0	0	0

Technical Analysis

RSI

44.66

MACD

9.36

50 DMA

1380.68

200 DMA

1495.34

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	1649.07	1493.37	1402.73	1337.67	1247.03	1181.97	1026.27
Fibonacci	1493.37	1433.89	1397.14	1337.67	1278.19	1241.44	1181.97
Camarilla	1354.92	1340.64	1326.37	1337.67	1297.83	1283.55	1269.28

Pivots Level: Classic

+311.40

1649.07

+155.70

1493.37

+65.07

1402.73

1337.67

Pivot Point

LTP: 1367.20

-90.63

1247.03

-155.70

1181.97

-311.40

1026.27

Moving Average

SMAEMA

Period

Value

10-EMA
1403.16
20-EMA
1396.56
30-EMA
1391.81
50-EMA
1393.37
100-EMA
1416.39
200-EMA
1442.91

Announcement Date	Purpose	Action	Ex Date
30 Apr 2026	agm
30 Apr 2026	board-meetings	Accounts, Quarterly Results
30 Jan 2026	dividend	₹3.50 Dividend /Share	05 Feb 2026
30 Jan 2026	board-meetings	Quarterly Results
05 Jan 2026	dividend	Interim Dividend - Rs. - 3.5	05 Feb 2026
12 Dec 2025	bonus	1:1 Bonus Issue of Equity Shares	12 Dec 2025
19 Nov 2025	bonus	Bonus issue 1:1	19 Dec 2025
31 Oct 2025	board-meetings	Quarterly Results, Half Yearly Results, Interim Dividend, Bonus Issue
31 Oct 2025	dividend	₹7.00 Dividend /Share	07 Nov 2025
07 Oct 2025	dividend	Interim Dividend - Rs. - 7	07 Nov 2025

Dr Lal Pathlabs Ltd

Narayana Hrudayalaya Ltd

Max Healthcare Institute Ltd

Aster DM Healthcare Ltd

Apollo Hospitals Enterprise Ltd

Fortis Healthcare Ltd

Dr Lal Pathlabs Ltd About

Dr. Lal PathLabs is engaged in the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations.

Industry

Healthcare

Founded

1995

Headquarters

CEO

Arvind Lal

Employees

Contact

Website

http://www.lalpathlabs.com

cs@lalpathlabs.com

Phone

91-011-3024 4149

Location

E-2 Block Sector 18, Rohini, New Delhi, New Delhi, 110085

Year	History
2017	Dr Lal PathLabs is Amalgameted with Ria and Pathology Private Limited
2018	Amalgamation of Shree Computerised Pathology Laboratory, Modern Diagnostics & Modern Lab
2021	Dr Lal PathLabs Launches Bangalore Reference Laboratory.
2023	NCLT has given approval for Amalgamation between Dr. Lal PathLabs Limited and APL Institute of Clinical Laboratory & Research Private Limited.
2024	NCLT, Allahabad Bench sanctioned the Scheme of Amalgamation between two Subsidiary Companies of Dr. Lal PathLabs Limited.

Client Name	Order Side	QTY	Avg Price	Date
MULTI-MANAGER ICVC	Sell	434943	2997.11	06 Jan 2025
SANJEEVINI INVESTMENT HOLDINGS	Sell	422494	840	15 May 2018
WAGNER LIMITED	Sell	1012870	730.02	24 Oct 2017
FRANKLIN TEMPLETON MUTUAL FUND	Buy	1048473	729.94	24 Oct 2017
WAGNER LIMITED	Sell	750000	780	29 Aug 2017
WAGNER LIMITED	Sell	1200000	780.72	30 Jun 2017
WAGNER LIMITED	Sell	900000	780.26	30 Jun 2017
WESTBRIDGE CROSSOVER FUND LLC	Sell	550100	950.02	17 Mar 2017
WESTBRIDGE CROSSOVER FUND LLC	Sell	1291920	950.27	01 Mar 2017
WAGNER LIMITED	Sell	1225260	1000.38	15 Feb 2017

Dr Lal Pathlabs Ltd News

Dr. Lal PathLabs Completes Shahbazkers Acquisition

Dr. Lal PathLabs Limited successfully completed 100% acquisition of Shahbazkers Diagnostic Centre Private Limited on May 01, 2026, making it a wholly owned subsidiary.

02 May 2026

companies

Dr. Lal PathLabs Completes Shahbazkers Acquisition

Dr. Lal PathLabs Limited successfully completed 100% acquisition of Shahbazkers Diagnostic Centre Private Limited on May 01, 2026, making it a wholly owned subsidiary.

01 May 2026

companies

Dr. Lal PathLabs Completes Acquisition of Shahbazkers

Dr. Lal PathLabs Limited has successfully completed the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited on May 01, 2026, making it a wholly owned subsidiary.

01 May 2026

companies

Dr. Lal PathLabs Publishes FY26 Financial Results

Dr. Lal PathLabs published newspaper advertisements for Q4 and FY26 financial results in Financial Express and Jansatta on May 01, 2026, pursuant to SEBI regulations.

01 May 2026

companies

Dr. Lal PathLabs Q4 Results: Revenue Grows, Profit Declines

Dr. Lal PathLabs Q4FY26 revenue rose to INR 7.00 billion, but net profit fell to INR 1.30 billion. FY26 revenue reached INR 27,629 million with profit of INR 5,098 million. Final dividend of INR 4.00 per share approved.

30 Apr 2026

companies

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800